
Michael J Satlin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9436905/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Characteristics of Covid-19 in New York City. New England Journal of Medicine, 2020, 382, 2372-2374.	13.9	1,836
2	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. American Journal of Transplantation, 2020, 20, 1800-1808.	2.6	683
3	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e4197-e4205.	2.9	337
4	The Global Challenge of Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancies. Clinical Infectious Diseases, 2014, 58, 1274-1283.	2.9	210
5	SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell, 2020, 38, 661-671.e2.	7.7	193
6	Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	178
7	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 731-741.	4.6	174
8	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2019, 322, 123.	3.8	143
9	Bacteremia and Blood Culture Utilization during COVID-19 Surge in New York City. Journal of Clinical Microbiology, 2020, 58, .	1.8	132
10	Bacterial Coinfections in Coronavirus Disease 2019. Trends in Microbiology, 2021, 29, 930-941.	3.5	128
11	Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nature Communications, 2019, 10, 5521.	5.8	123
12	Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infectious Diseases, The, 2022, 22, 401-412.	4.6	122
13	Widespread transfer of mobile antibiotic resistance genes within individual gut microbiomes revealed through bacterial Hi-C. Nature Communications, 2020, 11, 4379.	5.8	116
14	Comparative Effectiveness of Aminoglycosides, Polymyxin B, and Tigecycline for Clearance of Carbapenem-Resistant Klebsiella pneumoniae from Urine. Antimicrobial Agents and Chemotherapy, 2011, 55, 5893-5899.	1.4	111
15	Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia and Lymphoma, 2013, 54, 799-806.	0.6	111
16	Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. Journal of Infection, 2016, 73, 336-345.	1.7	108
17	Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a singleâ€centre study with focus on emerging pathogens. Mycoses, 2015, 58, 325-336.	1.8	94
18	Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clinical Infectious Diseases, 2020, 71, e523-e529.	2.9	94

#	Article	IF	CITATIONS
19	Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence, 2017, 8, 391-402.	1.8	92
20	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study. Open Forum Infectious Diseases, 2018, 5, ofy280.	0.4	83
21	Multidrugâ€resistant Enterobacteriaceae, <i><scp>P</scp>seudomonas aeruginosa</i> , and vancomycinâ€resistant <i>Enterococcus</i> : Three major threats to hematopoietic stem cell transplant recipients. Transplant Infectious Disease, 2017, 19, e12762.	0.7	72
22	Obesity and COVID-19 in New York City: A Retrospective Cohort Study. Annals of Internal Medicine, 2020, 173, 855-858.	2.0	72
23	Gut microbiota dysbiosis and diarrhea in kidney transplant recipients. American Journal of Transplantation, 2019, 19, 488-500.	2.6	70
24	Clinical Outcomes Associated with Polymyxin B Dose in Patients with Bloodstream Infections Due to Carbapenem-Resistant Gram-Negative Rods. Antimicrobial Agents and Chemotherapy, 2015, 59, 7000-7006.	1.4	66
25	First Report of <i>bla</i> _{VIM-4} - and <i>mcr-9</i> -Coharboring <i>Enterobacter</i> Species Isolated from a Pediatric Patient. MSphere, 2019, 4, .	1.3	58
26	Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Clinical Microbiology, 2020, 58, .	1.8	55
27	DAS181 for Treatment of Parainfluenza Virus Infections inÂHematopoietic Stem Cell Transplant Recipients at a Single Center. Biology of Blood and Marrow Transplantation, 2016, 22, 965-970.	2.0	52
28	Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i> _{NDM-5} : Preparation for a Postantibiotic Era. MBio, 2017, 8, .	1.8	50
29	Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem CellÂTransplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1808-1814.	2.0	49
30	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2533-2541.	1.3	48
31	The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. Leukemia and Lymphoma, 2016, 57, 2245-2258.	0.6	47
32	Pharmacodynamics of colistin and fosfomycin: a â€~treasure trove' combination combats KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2017, 72, 1985-1990.	1.3	43
33	Gut commensal microbiota and decreased risk for <i>Enterobacteriaceae</i> bacteriuria and urinary tract infection. Gut Microbes, 2020, 12, 1805281.	4.3	43
34	Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	37
35	Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. Journal of Clinical Virology, 2015, 71, 51-58.	1.6	36
36	Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2018, 67, 1720-1728.	2.9	34

#	Article	IF	CITATIONS
37	Impact of a Rapid Molecular Test for <i>Klebsiella pneumoniae</i> Carbapenemase and Ceftazidime-Avibactam Use on Outcomes After Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Clinical Infectious Diseases, 2022, 75, 2066-2075.	2.9	33
38	Evaluation of a Multiplex PCR Assay To Rapidly Detect Enterobacteriaceae with a Broad Range of β-Lactamases Directly from Perianal Swabs. Antimicrobial Agents and Chemotherapy, 2016, 60, 6957-6961.	1.4	31
39	The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leukemia and Lymphoma, 2014, 55, 2858-2865.	0.6	30
40	Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. Clinical Infectious Diseases, 2020, 70, 1240-1246.	2.9	29
41	Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. MBio, 2022, 13, e0275921.	1.8	27
42	Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2021, 73, 1257-1265.	2.9	24
43	Glycemic Control in HIV-Infected Patients with Diabetes Mellitus and Rates of Meeting American Diabetes Association Management Guidelines. AIDS Patient Care and STDs, 2011, 25, 5-12.	1.1	23
44	Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 5627-5630.	1.4	23
45	Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk. Leukemia and Lymphoma, 2019, 60, 1693-1696.	0.6	22
46	Gastrointestinal pathogen colonization and the microbiome in asymptomatic kidney transplant recipients. Transplant Infectious Disease, 2019, 21, e13167.	0.7	21
47	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. PLoS ONE, 2020, 15, e0236778.	1.1	21
48	The Search for a Practical Method for Colistin Susceptibility Testing: Have We Found It by Going Back to the Future?. Journal of Clinical Microbiology, 2019, 57, .	1.8	19
49	Gut microbiota profiles and fecal betaâ€glucuronidase activity in kidney transplant recipients with and without postâ€transplant diarrhea. Clinical Transplantation, 2021, 35, e14260.	0.8	18
50	Linking plasmid-based beta-lactamases to their bacterial hosts using single-cell fusion PCR. ELife, 2021, 10, .	2.8	18
51	Impact of a Multiplexed Polymerase Chain Reaction Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2020, 71, 1693-1700.	2.9	17
52	Impact of preâ€ŧransplant carbapenemâ€resistant <i>Enterobacterales</i> colonization and/or infection on solid organ transplant outcomes. Clinical Transplantation, 2021, 35, e14239.	0.8	17
53	American Society of Transplantation and Cellular Therapy Series, 1: Enterobacterales Infection Prevention and Management after Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 108-114.	0.6	15
54	New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14

#	Article	IF	CITATIONS
55	Languid Uptake of Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Infections and Continued Reliance on Polymyxins. Clinical Infectious Diseases, 2021, 72, 622-625.	2.9	14
56	Septic Shock Caused by Klebsiella pneumoniae Carbapenemase-Producing Enterobacter gergoviae in a Neutropenic Patient with Leukemia. Journal of Clinical Microbiology, 2013, 51, 2794-2796.	1.8	13
57	Epidemiology of Bloodstream Infections Caused by Escherichia coli and Klebsiella pneumoniae That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. Open Forum Infectious Diseases, 2018, 5, ofy300.	0.4	13
58	Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
59	Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles. Current Infectious Disease Reports, 2019, 21, 26.	1.3	10
60	Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy. Blood, 2019, 134, 1336-1336.	0.6	10
61	Apramycin resistance in epidemic carbapenem-resistant <i>Klebsiella pneumoniae</i> ST258 strains. Journal of Antimicrobial Chemotherapy, 2021, 76, 2017-2023.	1.3	9
62	Polymyxins. , 2017, , 1285-1288.e2.		7
63	Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	6
64	Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model. International Journal of Antimicrobial Agents, 2018, 52, 114-118.	1.1	5
65	1316. Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol in Critically Ill Patients. Open Forum Infectious Diseases, 2020, 7, S669-S670.	0.4	5
66	Closing the Brief Case: Disseminated Mycobacterium haemophilum Infection in a Kidney Transplant Recipient. Journal of Clinical Microbiology, 2018, 56, .	1.8	4
67	Reply to Rhoads, et al. Clinical Infectious Diseases, 2021, 72, e687-e687.	2.9	4
68	Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. Rheumatology Advances in Practice, 2021, 5, rkab014.	0.3	4
69	In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae. Frontiers in Microbiology, 2021, 12, 618087.	1.5	4
70	Sex-Related Differences in Clinical Presentation and Risk Factors for Mortality in Patients Hospitalized With Coronavirus Disease 2019 in New York City. Open Forum Infectious Diseases, 2021, 8, ofab370.	0.4	4
71	The Brief Case: Disseminated Mycobacterium haemophilum Infection in a Kidney Transplant Recipient. Journal of Clinical Microbiology, 2018, 56, .	1.8	3
72	Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. PLoS ONE, 2021, 16, e0257979.	1.1	3

#	Article	IF	CITATIONS
73	1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Infections under Cefiderocol Compassionate Use Program. Open Forum Infectious Diseases, 2021, 8, S717-S717.	0.4	3
74	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program. Open Forum Infectious Diseases, 2022, 9, ofab617.	0.4	3
75	Colonization with Vancomycin-Resistant Enterococci and Subsequent Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases, 2016, 3, .	0.4	2
76	636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States. Open Forum Infectious Diseases, 2019, 6, S295-S295.	0.4	2
77	Completing the Picture—Capturing the Resistome in Antibiotic Clinical Trials. Clinical Infectious Diseases, 2021, 72, e1122-e1129.	2.9	2
78	Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. Transplantation and Cellular Therapy, 2021, 27, 499.e1-499.e6.	0.6	2
79	Adenovirus viremia after <i>inÂvivo</i> T-cell depleted allo-transplant in adults: low lymphocyte counts are associated with uncontrolled viremia and fatal outcomes. Leukemia and Lymphoma, 2022, 63, 435-442.	0.6	2
80	434Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies. Open Forum Infectious Diseases, 2014, 1, S165-S165.	0.4	1
81	Colonization With Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae and Subsequent Risk of Bacteremia in Neutropenic Patients Undergoing Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases, 2015, 2, .	0.4	1
82	1826. Impact of Rapid Diagnostics and Ceftazidime–Avibactam on Mortality after Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2019, 6, S41-S41.	0.4	1
83	Machine Learning Highlights Downtrending of COVID-19 Patients with a Distinct Laboratory Profile. Health Data Science, 2021, 2021, .	1.1	1
84	Comparison between Perianal Swab and Stool Specimens for Detecting Colonization with Extended-Spectrum Beta-Lactamase-Producing and Fluoroquinolone-Resistant <i>Enterobacterales</i> . Journal of Clinical Microbiology, 0, , .	1.8	1
85	Worldwide challenges of multidrug-resistant bacteria in patients with hematologic malignancies. International Journal of Hematologic Oncology, 2013, 2, 377-390.	0.7	Ο
86	1581. Impact of Colonization with Fluoroquinolone-Resistant Enterobacteriaceae on the Risk of Gram-Negative Bacteremia in Hematopoietic Stem Cell Transplant Recipients Who Receive Prophylactic Levofloxacin. Open Forum Infectious Diseases, 2018, 5, S494-S494.	0.4	0
87	2686. strong>Bloodstream Infection Survey in High-Risk Oncology Patients (BISHOP) with Fever and Neutropenia (FN): Viridans Group Streptococcus Emerges as an Important Pathogen. Open Forum Infectious Diseases, 2019, 6, S943-S944.	0.4	Ο
88	2695. Pneumocystis jirovecii Pneumonia in the Era of Effective Prophylaxis Following Hematopoietic Stem Cell Transplant. Open Forum Infectious Diseases, 2019, 6, S947-S948.	0.4	0
89	Avoiding infections in transplant recipients: does the gut microbiota have a key role?. Expert Review of Clinical Immunology, 2020, 16, 113-115.	1.3	0
90	Real-world implementation and impact of a rapid carbapenemase detection test in an area endemic for carbapenem-resistant Enterobacterales. Infection Control and Hospital Epidemiology, 2022, 43, 92-95.	1.0	0

#	Article	IF	CITATIONS
91	532. COVID-19 Pneumonia in Patients with Hematologic Malignancies – A Report from the US Epicenter. Open Forum Infectious Diseases, 2020, 7, S333-S333.	0.4	Ο
92	Reply to Caldwell et al. Clinical Infectious Diseases, 2021, , .	2.9	0
93	Title is missing!. , 2020, 15, e0236778.		Ο
94	Title is missing!. , 2020, 15, e0236778.		0
95	Title is missing!. , 2020, 15, e0236778.		Ο
96	Title is missing!. , 2020, 15, e0236778.		0